Company intelligence / Profile preview
Nupathways
Evanston, Illinois, United Statesnupathways.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NuPathways is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for neuropsychiatric and neurological disorders. The company's primary focus is on modulating the N-methyl-D-aspartate (NMDA) receptor to treat conditions such as treatment-resistant depression (TRD). Its lead program, NPW-101, is an orally bioavailable NMDA receptor functional partial agonist designed to trigger rapid and sustained antidepressant effects. NuPathways was founded by the scientific team behind Naurex and Aptinyx, bringing extensive experience in synaptic plasticity and CNS drug development.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Nupathways.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nupathways.